ライフサイエンスコーパス: CD4 count

1 pression duration, and lowest presuppression CD4 count.

2 uced for all coinfected patients, regardless CD4 count.

3 outcome was not associated with the patient CD4 count.

4 n age at cancer diagnosis by AIDS status and CD4 count.

5 virologically suppressed patients with high CD4 count.

6 ental yield of LAM increased with decreasing CD4 count.

7 ng or at first clinical visit, regardless of CD4 count.

8 g, was higher in viremic patients with lower CD4 counts.

9 enuated among PHIV with lower VLs and higher CD4 counts.

10 and is associated with the highest absolute CD4 counts.

11 -related Cryptococcus presenting with higher CD4 counts.

12 ong ART-naive HIV-positive persons with high CD4 counts.

13 ssion by reducing viral loads and increasing CD4 counts.

14 ose who are virally suppressed and have high CD4 counts.

15 WH at low risk for TB exposure and with high CD4+ counts.

16 In patients with CD4 count 101-200 cells/mul, SILVAMP-LAM sensitivity was

17 RT)-treated individuals with a wide range of CD4 counts (137-1835 cells/mm(3)) indicated that neither

18 Of the remaining 1177 patients (median CD4 count 165 cells per muL [IQR 75-271]), 163 (14%) had

19 % female, 49% African; median age, 34 years; CD4 count, 173 cells/muL; and plasma HIV-1 RNA, 5.0 log

20 <200 cells/muL (44%), patients with current CD4 count 200-350 vs >500 cells/muL had aIRRs of 1.44 du

21 >=500 cells/uL (3.3%) compared to those with CD4 count 200-499 cells/uL (9.2%) between months 18 and

22 gical outcomes, being better than those with CD4 counts 200-499 cells/uL.

23 age 35 years [IQR 29-41], median enrollment CD4 count 280 cells/mul [IQR 146-431]) were included in

24 ts in Kenya (median [IQR] age 35 [29-43] and CD4 count 283 [117-541]; 58% female).

25 asma viral load [pVL] >50,000 RNA copies/ml; CD4 counts 283 cells/mm(3), n = 47) and relatively contr

26 00 patients (median [IQR] age 34 [29-40] and CD4 count 286 [128-490]; 63% female) in South Africa and

27 age 35 [29-43]; 63% (n = 373) female; median CD4 count 293 [133-487]).

28 ipants (hazard ratio for death, adjusted for CD4 count, 3.0; 95% confidence interval, 1.4-6.7; P = .0

29 lack, 13% Hispanic; median age was 37 years, CD4 count 321 cells/microL, and viral load 4.5 log10 cop

30 ral load (4.5 log10 copies/mL both arms) and CD4 count (343 vs 466 cells/mm3) were observed between D

31 In addition, a lower CD4 count (350-499) at baseline was associated with a ri

32 eased coinfected patients had higher initial CD4 count (417 +/- 219 cells) than monoinfected ones wit

33 eased coinfected patients had higher initial CD4 count (417+/-219 cells) than singly-infected ones wi

34 th retention than not having an ART-eligible CD4 count (50% versus 32%), an intention-to-treat risk d

35 65% female, median age 38 years, and median CD4 count 506 cells/mm3.

36 Sixty patients were included (median CD4 count 53 cells/microL (interquartile range [IQR], 22

37 Among 1510 PLWH (median CD4+ count 532 cells/mm3), estimated LTBI prevalence was

38 ntrolled disease (pVL <10,000 RNA copies/ml; CD4 counts 657 cells/mm(3), n = 49).

39 g those not newly diagnosed, but with median CD4 count 75 cells/uL and high HIV viral loads.

40 nts (551 vs. 437 cells/mm3, P<.001), similar CD4+ counts (864 vs. 880 cells/mm3, P=.5) and lower CD4+

41 th retention than not having an ART-eligible CD4 count (91% versus 21%), a complier causal risk diffe

42 otential confounders and mediators including CD4 count, a substantially higher mortality rate was pre

43 technologies for the measurement of absolute CD4 count (AbsCD4), CD4 percentage (CD4%) and total hemo

44 Nadir and enrollment CD4 counts, activated T-cells, and time on ART were simi

45 /622), with detection more likely with lower CD4 counts(adjusted odds ratio [AOR] 1.02 per 10 cells/m

46 se, human immunodeficiency virus status with CD4 count, age, serum albumin, body mass index, and pre-

47 rugs, ART initiation year, and baseline age, CD4 count, AIDS, duration of ART) all-cause and cause-sp

48 no significant associations with viral load, CD4 counts, AIDS, cancer, or mortality in both cohorts b

49 We calculated incidence rates stratified by CD4 count and cART status and conducted a case-control s

50 We aimed to identify key CD4 count and HIV RNA (viral load) predictors of risk fo

51 on to HIV disease-related factors, including CD4 count and viral load (VL), are unknown.

52 sequent management and evaluate post-failure CD4 count and viral load trends.

53 t, cumulative, and nadir or peak measures of CD4 count and viral load, using demographics-adjusted, c

54 Treatment group differences in CD4 count and viral suppression were similar in SMART an

55 in each trial led to similar differences in CD4 count and viral suppression.

56 g extended Cox regression models with recent CD4 count and VL analyzed as time-changing covariates.

57 mine risk of subsequent NMSCs in relation to CD4 count and VL.

58 treatment programme, year of ART initiation, CD4 count and WHO clinical stage at ART initiation, rete

59 Thus, after adjustment for differences in CD4 counts and age, hrHPV prevalences were more similar

60 trong correlation between CCR5 CRPA and both CD4 counts and CD4 T cell apoptosis.

61 stingly, CCR5 CRPA correlated inversely with CD4 counts and CD4:CD8 ratio specifically in viremic pat

62 Although 1-year post-HCT median CD4 counts and freedom from IV immunoglobulin were impro

63 response relationship between risk and lower CD4 counts and higher VLs.

64 We compared HIV RNA levels, CD4 counts and percentages, lipids, and growth across gr

65 rs), thus confirming their independence from CD4 counts and pVL.

66 Baseline CD4 counts and screening for opportunistic infections, s

67 LA-B*52:01 was associated with high absolute CD4 counts and therefore a lack of HIV disease progressi

68 ised to monitoring with or without 12-weekly CD4 counts and to receive 2 nucleoside reverse transcrip

69 association of antiretroviral therapy (ART), CD4+ count and human immunodeficiency virus (HIV) plasma

70 viremia <0.6 HIV-1 RNA copies/mL had higher CD4+ counts and lower levels of T-cell activation than t

71 Antiretroviral therapy (ART) restores CD4+ counts and may have beneficial effects on gut micro

72 art [HR 1.58, 95% CI 1.47-1.69], most recent CD4 count) and retention (ART club membership, baseline

73 PLWH and examines associations between AIDS, CD4 count, and age at cancer diagnosis.

74 which evaluated POC testing for viral load, CD4 count, and creatinine, with task shifting from profe

75 sex, age, nationality, time on ART, baseline CD4 count, and employment status.

76 Age, BMI >= 25 kg/m2, low nadir CD4 count, and history of IVDU emerged as possible risk

77 inflammatory markers including suPAR, nadir CD4 count, and prevalence of age-associated noncommunica

78 race, HIV risk group, calendar year, cohort, CD4 count, and viral load.

79 rated rapid, point-of-care HIV screening and CD4 counts, and in-parallel viral load testing, to promo

80 human immunodeficiency virus (PLWH) with low CD4 counts are at high risk for immune reconstitution in

81 IV) in HIV-infected pregnant women with high CD4 counts are lacking.

82 After adjusting for demographics, VL, CD4 counts, ART regimen, prior use of mono or dual antir

83 was 36 years, 48.9% were female, and median CD4 count at admission was 61 (IQR 21-145).

84 emale, 61% were aged 30-49 years, and median CD4 count at ART initiation was 268 cells/muL.

85 emale, 65% were aged 30-49 years, and median CD4 count at ART initiation was 270 cells/muL.

86 oor CD4 count documentation and lower median CD4 count at ART initiation was associated with increase

87 creased from 300 to 362 cells/uL, and median CD4 count at ART prescription increased from 160 to 364

88 conclusion, the CRF01_AE subtype and a lower CD4 count at baseline tend to be associated with the fas

89 multiplicatively with transmission routes or CD4 count at baseline to contribute to HIV/AIDS progress

90 cells, p=0.004), while survivors had similar CD4 count at baseline, regardless HTLV status.

91 The median CD4 count at diagnosis increased from 326 (Interquartile

92 The median CD4 count at diagnosis increased from 326 (interquartile

93 Projected outcomes included CD4 count at diagnosis, primary HIV transmissions from a

94 scription declined from 69 to 6 days, median CD4 count at entry into care increased from 300 to 362 c

95 e 5-year survival probability, stratified by CD4 count at failure, was estimated with targeted maximu

96 l-based comparison between current standard (CD4 count at presentation of 0.260 x 109 cells/L, univer

97 RT initiation (4.8 versus 5.0 years), median CD4 count at study enrollment (506 versus 533 cells/mm3)

98 particularly important for patients with low CD4 counts at failure.

99 de comparisons, patients with TAMs had lower CD4 counts at treatment initiation than did patients wit

100 th weight gain in all participants: baseline CD4 count, baseline human immunodeficiency virus type 1

101 male and below 35 years of age and having a CD4 count below 200 cells/muL prior to start of ART were

102 inical impact of IRIS in adults with HIV and CD4 counts below 100 cells/uL starting ART, we designed

103 ations were observed between salivary pH and CD4+ count (beta: -0.645, 95% CI: 0.02, 1.25) and betwee

104 306) entering clinical HIV care with a first CD4 count between 12 August 2011 and 31 December 2012 in

105 CD4 counts between 200-500 cells/uL (mHR: 0.5, 95% CI: 0

106 s (aIRRs) comparing patients by time-updated CD4 count category, adjusted for cohort, age, gender, ca

107 virus coinfection, group of exposure, nadir CD4 count, CD4:CD8 ratio, and last CD4 level, calendar p

108 Among patients with CD4 counts close to the 350-cells/mul threshold, having

109 005), even after adjusting for age and nadir CD4 count.CONCLUSIONHIV-infected cells persist in CSF in

110 CD4 count decreased by a median of -130 cells per muL (r

111 deficiency virus (PWH) with persistently low CD4 counts despite efficacious antiretroviral therapy co

112 tive of future CVD events but independent of CD4 counts, diabetes, age, and birth sex, suggesting tha

113 fewer women on ART, and in cohorts with poor CD4 count documentation and lower median CD4 count at AR

114 cumented transfers, and in cohorts with poor CD4 count documentation, whereas higher patient load was

115 Studies suggest that CD4 counts early in HIV infection do not predict relevan

116 n HIV care than patients who just missed the CD4-count eligibility cutoff.

117 Virologically suppressed patients with lower CD4 counts experienced higher hospitalization rates and

118 ment (immediate treatment arm) or when their CD4 count fell below 350 cells/uL (deferred treatment ar

119 The decision to start ART was determined by CD4 count for one in four patients (25%) presenting clos

120 -randomised cohort died; the median baseline CD4 count for participants who died was 11 cells per muL

121 CD4 counts for ART initiation were necessary when medica

122 Mean increases in CD4 counts from baseline at week 96 were 205 cells per m

123 eroid response, whereas a larger increase in CD4+ count from baseline to 1 to 3 months corresponded t

124 table partners, extending ART to people with CD4 count greater than or equal to 500 cells per mm(3),

125 In those with CD4 count > 200 cells/mul, SILVAMP-LAM sensitivity was 4

126 -1-infected adults on ART for >/= 18 mo with CD4 count > 350 cells/mm3 in a malaria-endemic region in

127 10, who were followed from the date they had CD4 count >/=350 cells/muL and were virologically suppre

128 1.08-1.34, p = 0.001), and having a baseline CD4 count >350 cells/uL (HR 2.37, 95% CI 1.94-2.89.

129 CI, .41-.63]) vs 0.93 [95% CI, .76-1.13] for CD4 count >350 cells/uL).

130 Among YLPHIV, CD4 count >500 cell/mm3 (RR, 1.04; P = .76), VL (RR, 1.0

131 Among patients with lowest presuppression CD4 count >=200 (56%), patients with current CD4 351-500

132 ently lower among participants with baseline CD4 count >=500 cells/uL (3.3%) compared to those with C

133 ently lower among participants with baseline CD4 count >=500 cells/uL (adjusted hazard ratio [aHR], 0

134 S was >=94% among participants with baseline CD4 count >=500 cells/uL at all 6-month intervals to 30

135 s aged 18-70 years with controlled HIV (with CD4 counts >200 cells per muL and HIV-1 RNA <200 copies

136 9-3.0]), the incidence rate in patients with CD4 counts >500 cells/muL remained higher compared with

137 nfected, nonbreastfeeding women with pre-ART CD4 counts >=400 cells/muL who started ART during pregna

138 ffer by HIV control (virally suppressed with CD4 counts >=500 cells/mm3 or not) in adjusted stratifie

139 s concerns, participants initiating ART with CD4 counts >=500 cells/uL had very good virological outc

140 adults with sustained viral suppression and CD4 counts >=500 cells/uL were consecutively analyzed fo

141 s on suppressive antiretroviral therapy with CD4+ counts >350 cells/muL and detectable plasma HIV-1 R

142 ated HIV/AIDS progression compared to higher CD4 count (>/=500) (HR = 4.38, 95%CI: 1.95-9.82, P < 0.0

143 ART-naive persons with high CD4 counts (>500 cells/uL) from 222 clinical sites in 35

144 ant evidence among women with a higher nadir CD4+ count (>=350 cells/ul vs <200 cells/ul [adjusted ha

145 well as multivariate analyses included a low CD4 count, high viral load, and not being a Spanish-spea

146 were adjusted for demographics, viral loads, CD4 counts, history of opportunistic infections, and vas

147 for overall non-Hodgkin lymphoma were recent CD4 count (ie, lagged by 6 months; <50 cells per muL vs

148 significantly associated with the patient's CD4 count in both fitted models.

149 HHC was significantly associated with higher CD4 counts in patients.

150 ssociated with significantly higher absolute CD4 counts in the donors (median, 941.5 cells/mm(3); P =

151 on of 25 cells per muL and provides accurate CD4 counts in the range of 25-800 cells per muL.

152 anges were independent of viral replication, CD4 counts, inflammation, and type of antiretroviral tre

153 CD4 count information plays a vital role in the effectiv

154 etection, no ART or delayed initiation (when CD4 count is <0.350 x 109 cells/L), reduced investment i

155 TION: Decreasing monitoring to annually when CD4 count is higher than 200 cells per muL compared with

156 n retention between patients presenting with CD4 counts just above versus just below the 350-cells/mu

157 h rates, survival time, baseline and current CD4 count, last HIV-1 RNA plasma viral load (VL) and cau

158 L (lower limit of normal) and 11 (55%) had a CD4 count less than 200 cells/muL; 11 (55%) subjects had

159 reening test for people living with HIV with CD4 count less than or equal to 350 cells per muL who ar

160 nfirmed TB including 101 (49%) patients with CD4 counts less than or equal to 100 cells/mul.

161 mong consecutive people living with HIV with CD4 counts less than or equal to 350 cells/mul initiatin

162 n antiretroviral treatment (ART) coverage at CD4 count lower than 500 cells per mm(3) and greater tha

163 00 PYs difference), those who had an initial CD4 count < 100 cells/mul (+9.2 deaths/100 PYs differenc

164 human immunodeficiency virus (HIV) disease (CD4 count < 200 cells/uL) remained common (24% of those

165 venous drug use (IVDU) (P = .033), and nadir CD4 count < 350 cells/mm3 (P = .055).

166 deferred ART eligibility, as determined by a CD4 count < 350 cells/mul, per South African national gu

167 initiation of ART within 3 mo in those with CD4 count </= 350 cells/mul did not differ significantly

168 ses, including 6 stratified by preenrollment CD4 count </=200 cells/muL, were analyzed and compared t

169 Sixteen (80%) subjects had a CD4 count </=441 cells/muL (lower limit of normal) and 1

170 Health Organization Stage 1 or 2 disease and CD4 count </=500 cells/mm3.

171 In regression modeling, having a CD4 count </=700 cells/mm(3) contributed to a 2.1 mm Hg

172 have an IOP </=10 mm Hg, and patients with a CD4 count </=700 cells/mm(3) were 13 times more likely t

173 immunodeficiency virus-positive persons with CD4 count <100 cells/muL initiating antiretroviral thera

174 when analysis was restricted to persons with CD4 count <100 cells/muL.

175 6-11) suppression and lowest presuppression CD4 count <200 and >=200 cells/uL, Poisson regression mo

176 oma diagnosis (difference = 4; P = .01), and CD4 count <200 cells/microL (vs >/=500) was associated w

177 biomarker of more severe immune deficiency (CD4 count <200 cells/mL) had a 44% increased risk of sub

178 P < .01) and more likely to have a pregnancy CD4 count <200 cells/mm3 (19% vs 11%, P = .01).

179 Among patients with lowest presuppression CD4 count <200 cells/muL (44%), patients with current CD

180 eased with age, low CD4/CD8 ratio, and nadir CD4 count <200 cells/muL but was not associated with cal

181 ), older, had HIV RNA >400 copies/mL, or had CD4 count <200 cells/muL had higher hospitalization rate

182 HIV-infected adults with CD4 count <200 cells/muL were randomized to either CrAg

183 ensitivity analysis excluded PLWH with nadir CD4 count <200 cells/muL.

184 ith older age, CD4/CD8 ratio <0.8, and nadir CD4 count <200 cells/muL.

185 and 3-fold higher among those with baseline CD4 count <200 cells/uL (aHR, 3.49; P < .0001).

186 ), older, had HIV RNA >400 copies/mL, or had CD4 count <200 cells/uL had higher hospitalization rates

187 erson-years among participants with baseline CD4 count <200, 200-499, and >=500 cells/uL, respectivel

188 In multivariable analysis, baseline CD4 count <350 cells/mm3, female sex, and lower baseline

189 Fifty-one of 1452 participants with baseline CD4 count <350 cells/muL developed IRIS.

190 sk for diffuse large B-cell lymphoma (recent CD4 count <50 cells per muL vs >=500 cells per muL, HR 2

191 (VL) was 4.83 copies/mL with 21.7% having a CD4 count <500 cell/mm3; median duration on ART was 9.8

192 dian age was 37 years (IQR 30-43), 43% had a CD4 count <= 100 cells/mul, and 35% were receiving antir

193 In patients with CD4 count <= 100 cells/mul, SILVAMP-LAM sensitivity was

194 of SILVAMP-LAM was highest in patients with CD4 count <= 100 cells/mul.

195 d confirmatory testing with urine TB-LAM (if CD4 count <=100 cells/mul), sputum Xpert, and/or a singl

196 ts against TB disease observed in women with CD4 count <=350 cells/muL.

197 nd US$91 (95% CI, $49-$443) among those with CD4 counts <100 cells /muL.

198 o ADCs and NADCs were highest for PWHIV with CD4 counts <100 cells/mm3.

199 ated the clinical impact of IRIS in PLWH and CD4 counts <100 cells/muL starting ART in an internation

200 (ratio of 1:2) patients living with HIV with CD4 counts <100 cells/uL attending 2 hospitals in Johann

201 ized HIV-infected tuberculosis patients with CD4 counts <350 cells/microL were included; tuberculosis

202 DNAemia >=1000 copies/mL was associated with CD4 counts <350 cells/uL.

203 AP occurred more frequently in patients with CD4 counts <500 cells/muL (incidence rate ratio [IRR], 6

204 Risk factors for CAP were older age, CD4 counts <500 cells/muL, smoking, drug use, and chroni

205 tive cohort study, 30 HIV-infected patients (CD4+ count <100 cells/uL) underwent FDG-PET/CT scans at

206 Patients with a CD4+ count <200 cells/mm3 had a lower CR rate.

207 ], .37-.72) and had a higher likelihood of a CD4+ count <200 cells/uL (aOR, 1.53; 95% CI, 1.17-2.00).

208 PLWH with a CD4+ count <300 cells/mm3 underwent standardized neurolo

209 HIV-related risk factors were low CD4 count (<200 cells per muL), detectable plasma HIV RN

210 A lower CD4 count (<200 cells/mm3) was associated with the prima

211 -cells/mul threshold, having an ART-eligible CD4 count (<350 cells/mul) was associated with higher 12

212 0 copies per mL, or >400 000 copies per mL), CD4 count (<50 cells per muL, 50-199 cells per muL, or >

213 teriaceae (P = .02) in participants with low CD4+ counts (<400 cells/mm3).

214 fits of offering immediate ART regardless of CD4 count may be larger than suggested by clinical trial

215 Absolute CD4 counts may play a role in IOP fluctuations.

216 ver, current evidence suggests that although CD4 counts may still play a role in guiding clinical car

217 7 versus 33 years), and tended to have lower CD4 counts (median 220 versus 289 cells/mul) at the time

218 e ART use and early initiation at high nadir CD4 counts might reduce anal high-risk HPV infection and

219 14 years, on ART >6 months, not acutely ill, CD4 count not <200 cells/mm3) and willingness to partici

220 Current CD4 count of <=200 cells/muL was the strongest predictor

221 fected sputum-expectorating patients (median CD4 count of 130 cells/ml) from a previously published r

222 ale (N = 11,241), they had median enrollment CD4 count of 220 cells/mul, and 38% had WHO stage 1 clin

223 Women had a median CD4 count of 537 cells/mul (IQR: 483 to 741) at enrollme

224 ) on a stable regimen for at least 6 months, CD4 count of more than 100 cells per muL, and no history

225 d <.001) so that the percentage of WLWH with CD4 counts of >=500 cells/muL increased from 7.7% in 200

226 rom the standard of care (ART eligibility at CD4 counts of <350 cells/mm3 until September 2016 and <5

227 e HIV-positive adults (aged >=18 years) with CD4 counts of 150 cells per muL or less, who had not had

228 The strategies were defined by the threshold CD4 counts of 200 cells per muL, 350 cells per muL, and

229 with linkage to care with ART initiation at CD4 counts of 350 cells per muL or less reduces HIV inci

230 lasma HIV-1 RNA; women not receiving ART had CD4 counts of 350 cells per muL or less.

231 ncentrations of at least 1000 copies per mL, CD4 counts of at least 200 cells per muL, estimated glom

232 nal ART-eligibility guidelines expanded from CD4 counts of less than 350 cells per muL (Oct 1, 2014-D

233 with a median cluster of differentiation 4 (CD4) count of 58 cells/L (IQR = 21-120) and a median HIV

234 HIV-1 RNA >100 000 copies/mL, with a median CD4+ count of 202 cells/mm3.

235 ies/mL in 64% of participants, with a median CD4+ count of 208 cells/mm3; for EFV (n = 44), 55% of pa

236 ed previous ART and were starting ART with a CD4+ count of fewer than 100 cells per cubic millimeter.

237 .8) of antiretroviral therapy experience and CD4+ counts of median 640 cells/mm3 (interquartile range

238 among either cohort, and no correlation with CD4 count or HAND status for the HIV-infected cohort.

239 viously diagnosed partners with no report of CD4 count or viral load in the preceding 12 months were

240 ted individuals, particularly those with low CD4 counts or high VLs.

241 d this outcome appeared to be independent of CD4+ count or WHO stage.

242 There were no significant changes in CD4+ counts or HIV DNA.

243 studies investigated the association of ART, CD4+ count, or HIV PVL on histology-confirmed CIN2+ dete

244 th detectable HIV viremia and inversely with CD4 count (p<0.0001), consistent with HIV activation of

245 nd HIV risk group (p<0.0001); higher pre-ART CD4 count (p=0.0008) and pre-ART viral load (p=0.0003) w

246 analysis, after controlling for most recent CD4 count, pregnancy incidence rates were higher in wome

247 ilure, in particular high viral load and low CD4 counts remain similar to older treatments.

248 rt prophylaxis for opportunistic infections, CD4 counts should cease to be required for ART initiatio

249 Patients with HIV and low CD4 counts starting antiretroviral therapy (ART) are at

250 th AHD (CD4 cell count, <=200/mul) receiving CD4 count testing, whole blood was tested for CrAg by Cr

251 ode (600 vs. 540) and mean (741.9 vs. 712.2) CD4 + counts than males at baseline.

252 g, linkage to care, ART (started at a higher CD4 count than in standard care), and increased access t

253 d the square root of the first pre-treatment CD4 count to time of serconversion though a linear mixed

254 ed the square root of the first pretreatment CD4 count to time of seroconversion through a linear mix

255 (95% CI, $43-$211) for all participants with CD4 count up to 200 cells/muL and US$91 (95% CI, $49-$44

256 long-term ART, 308/378 (81%) monitored with CD4 counts versus 297/375 (79%) without had VL <1,000 co

257 ted for measured time-varying confounding by CD4 count, viral load, and visit frequency.

258 ed women after controlling for maternal age, CD4 count, viral load, antiretroviral regimen, body mass

259 ed women after controlling for maternal age, CD4 count, viral load, antiretroviral regimen, body mass

260 Measured CD4 count, VL, and subsequent NMSC (BCC and SCC).

261 (95% CI: 20.9, 32.3) for no switch (51.1% if CD4 count was <100 cells/mm3).

262 CD4 cell count with protection conferred if CD4 count was <=350 cells/muL (aHR, 0.51 [95% CI, .41-.6

263 d documentation of HIV infection, and median CD4 count was 139 cells per muL (IQR 63-271).

264 antiretroviral therapy (ART), and the median CD4 count was 149 cells/microL.

265 Median nadir CD4 count was 246 cells/mm3; median age was 48 years; 17

266 g patients was 35 years, the median baseline CD4 count was 262 cells/mul, and 37.2% were men.

267 Median age was 37 years, and CD4 count was 29 cells/muL.

268 Median CD4 count was 310 cells per muL (IQR 179-424).

269 The mean age was 32 years, and the mean CD4 count was 337 cells per cubic millimeter.

270 bonucleic acid was 4.56 log10 copies/mL, and CD4 count was 338 cells/uL.

271 The mean CD4 count was 396 cells/mm3 (SD = 61) for those enrolled

272 Median CD4 count was 430 (IQR, 190-620) cells/microL.

273 The patient's CD4 count was 430 cells per muL (23.5% of total T cells)

274 Median CD4 count was 577 (interquartile range, 397-820) cells/m

275 edian age was 73 years, 75% were men, median CD4 count was 578 cells/muL, and 94% had controlled vire

276 e of 51 years; 83% were male; and the median CD4 count was 602 cells/muL.

277 ry was 51 years; 19% were female; the median CD4 count was 616 cells/uL; and HIV-1 RNA was <200 copie

278 Median CD4 count was 62 (range, 0-526) cells/muL; KSHV seroposi

279 The median CD4 count was 651, and 5.3% had HIV RNA <= 200.

280 onfirmed tuberculosis was 62% and the median CD4 count was 86 cells per muL.

281 hospitals in Cape Town, South Africa: median CD4 count was 97 cells/muL, 64% were women, and 38% were

282 age, hepatitis B and hepatitis C status, and CD4 count was abstracted from clinical records from Sind

283 n this subpopulation, having an ART-eligible CD4 count was associated with higher 12-month retention

284 CD4 count was lower both at initiation of antiretroviral

285 CD4 count was lower both at initiation of ART and at VF

286 Higher CD4 count was protective despite an increased propensity

287 However, recent CD4 count was the sole key predictor of risk for CNS non

288 ars), almost 62% were female, and the median CD4+ count was 173 cells/mul (IQR 92-254 cells/mul).

289 ral therapy (ART) in Zambia, median baseline CD4+ count was 202 cells/mm3 and 41.6% were hepatitis B

290 years, 53.7% were women, and median baseline CD4+ count was 240 cells/mm3.

291 nts, 311 (77%) had HIV infection; the median CD4+ count was 340 cells per cubic millimeter (interquar

292 The median baseline CD4+ count was 37 cells per cubic millimeter, but 854 pa

293 f these patients, 54% were women; the median CD4+ count was 470 cells per cubic millimeter, and half

294 class, a higher viral load (VL), and a lower CD4 count were associated with higher NT-proBNP concentr

295 Among PHIV, VLs and CD4 counts were associated with NT-proBNP concentrations

296 We compared virological outcomes by pre-ART CD4 count, where universal ART initiation was provided i

297 s clinical status, pregnancy, and enrollment CD4 count, which precluded the assessment of rapid ART i

298 secutively recruited CM patients with normal CD4 counts who achieved microbiologic control.

299 patients and an inverse correlation between CD4 count with the frequency of CD4(+)Gal-9(+) T cells w

300 er TL1A nor DR3 levels reflected recovery of CD4 counts with cART.

301 /270) of the women who were HIV-positive had CD4 counts within National Department of Health ART init